

Active substances set



Search phrase: rituximab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

non-Hodgkin lymphoma

Rituximab



Rituximab is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy. Rituximab maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. Rituximab monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. Rituximab is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's Lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. Rituximab in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).

-  FULL REIMBURSEMENT
-  ESMO

Multiple myeloma and plasma cell neoplasms

Rituximab

Rituximab is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy. Rituximab maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. Rituximab monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are

-  FULL REIMBURSEMENT
-  ESMO

chemoresistant or are in their second or subsequent relapse after chemotherapy. Rituximab is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. Rituximab in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).

Chronic lymphoid leukemia

Rituximab

Rituximab in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory CLL. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including Rituximab or patients refractory to previous Rituximab plus chemotherapy.

